NCT02033525View on ClinicalTrials.gov

Mesenchymal Stromal Cells for Degenerative Meniscus Injury

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

May 2, 2017

Study Completion Date

May 2, 2017

Conditions

Chronic Meniscal Injury

Interventions

DRUG

XCEL-M-ALPHA and standard rehabilitation

Intraarticular infusion of autologous bone marrow derived ex vivo expanded mesenchymal stromal cells produced at Xcelia (Advanced Therapies Division of the Blood and Tissue Bank)

OTHER

Rehabilitation

Standard rehabilitation program

Trial Locations (1)

08028

ICATME-Hospital Quiron Dexeus, Barcelona

All Listed Sponsors

collaborator

Hospital Universitari Quirón Dexeus

UNKNOWN

collaborator

Ministerio de Sanidad, Servicios Sociales e Igualdad

OTHER_GOV

lead

Banc de Sang i Teixits

OTHER

NCT02033525 - Mesenchymal Stromal Cells for Degenerative Meniscus Injury | Biotech Hunter | Biotech Hunter